Roche has announced that a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam) has been ...

Roche’s Evrysdi tablet receives US FDA approval for the treatment of spinal muscular atrophy: Basel Friday, February 14, 2025, 13:00 Hrs [IST] Roche, announced that the US Food ...

Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

The company made an upfront payment and will provide success-based milestones and royalties in exchange for global rights.

AI accelerates drug development, cutting costs and boosting success rates. Discover how AI is reshaping the future of ...

Market OverviewThe Orphan Drugs Market is a specialized sector within the pharmaceutical industry that focuses on the ...

Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...

So far, that hasn’t been an issue with Roche’s drug or another BTK from Novartis called remibrutinib. All four drugs are in phase 3 testing, in a closely-fought contest to bring a new oral ...

The drug has been listed among Clarivate's drugs to watch in 2023. Ipatasertib was initially discovered by Roche subsidiary Genentech in collaboration with Array BioPharma. Also listed among ...